Latest news
Volunteers needed to test home monitoring app
Posted: Thursday 7 September 2023
Digital health company, OKKO Health, is calling for more volunteers to help test a new app which could revolutionise eye care for people living with macular disease.
Find out more
Is blue light damaging and are filters worth it?
Posted: Friday 1 September 2023
We often get asked whether blue light is dangerous to the macula and whether blue light filtering glasses are worth getting. Recent research has shown that blue light filters often do not live up to the claims they make.
Find out more
Second drug for dry AMD becomes available in the US
Posted: Tuesday 8 August 2023
Another new drug to treat late-stage dry age-related macular degeneration (AMD) has been approved for use in the US.
Find out more
Macular Society supports Edge Hill University's groundbreaking AMD research
Posted: Friday 7 July 2023
Macular Society Trustees have visited Edge Hill University’s labs to talk to its world-leading researchers on age-related macular degeneration (AMD).
Find out more
Breakthrough AI technology could boost diagnosis and treatment of macular disease
Posted: Monday 19 June 2023
A groundbreaking project harnessing the power of artificial intelligence (AI) has the potential to revolutionise both the diagnosis and treatment of macular disease, according to researcher professor Adam Dubis.
Find out more
Stargardt pill could slow progression of disease
Posted: Wednesday 10 May 2023
A new drug to treat Stargardt disease has helped to slow down the progression of the condition in some patients, according to the latest results of a phase two clinical trial.
Find out more
Biosimilars - the cheaper drugs for macular degeneration
Posted: Wednesday 3 May 2023
As patents for existing drugs to treat wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO) expire we hear from professor Richard Gale, on what this means for patients and ophthalmology services.
Find out more
New drug for dry AMD - Syfovre: your questions answered
Posted: Tuesday 4 April 2023
In February we shared the exciting news that the first-ever drug to treat dry age-related macular degeneration (AMD) has been approved in the US. With the support of Apellis Pharmaceuticals, which has brought the drug to market, we answer some of your most frequently asked questions.
Find out more
Workforce Census illustrates severe shortage of eye doctors
Posted: Friday 31 March 2023
The Macular Society has reacted with concern to The Royal College of Ophthalmologist’s 2022 Workforce Census, which reveals the shortage of eye doctors in the UK and the extent of pressure on NHS ophthalmology services.
Find out more
Rare Disease Day 2023: Gene-editing for Stargardt disease a ‘step in the right direction’
Posted: Tuesday 28 February 2023
A PHD student believes that new gene therapy technologies could at some point pave the way for a treatment or a cure.
Find out more
First-ever AMD audit highlights importance of regular injections
Posted: Monday 27 February 2023
The UK’s first-ever audit of hospital eye care services for patients with wet age-related macular degeneration (AMD) has confirmed regular injections help stabilise vision in most patients and early diagnosis and treatment are vital.
Find out more
First drug to treat dry AMD approved for use in US
Posted: Tuesday 21 February 2023
The first ever drug to treat dry age-related macular degeneration (AMD) has been approved for use in the US.
Find out more
Get the latest news and advice from the Macular Society
To hear about life-changing research, treatments and tips for living with sight loss, subscribe to our monthly enewsletter today. Together we can Beat Macular Disease.
Sign up to our free email newsletter
